This suggests that GC patients with HER2-positive and TP53-mutated may require different treatment approaches compared to other patients, such as combined anti-HER2 antibody (3, 7) and p53 activators, such as APR-246 (25, 26). This evidence concerns the gene ERBB2 and gastric cancer.